

# PLD2 Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a partial recombinant PLD2. Catalog # AT3337a

## **Product Information**

Application	WB, E
Primary Accession	<u>014939</u>
Other Accession	<u>BC015033</u>
Reactivity	Human, Rat
Host	mouse
Clonality	monoclonal
Isotype	IgG2a Kappa
Clone Names	1C5
Calculated MW	105987

### **Additional Information**

Gene ID	5338
Other Names	Phospholipase D2, PLD 2, hPLD2, Choline phosphatase 2, PLD1C, Phosphatidylcholine-hydrolyzing phospholipase D2, PLD2
Target/Specificity	PLD2 (AAH15033, 834 a.a. ~ 933 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Dilution	WB~~1:500~1000 E~~N/A
Format	Clear, colorless solution in phosphate buffered saline, pH 7.2 .
Storage	Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Precautions	PLD2 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.

# Background

Phosphatidylcholine (PC)-specific phospholipases D (PLDs; EC 3.1.4.4) catalyze the hydrolysis of PC to produce phosphatidic acid and choline. Activation of PC-specific PLDs occurs as a consequence of agonist stimulation of both tyrosine kinase and G protein-coupled receptors. PC-specific PLDs have been proposed to function in regulated secretion, cytoskeletal reorganization, transcriptional regulation, and cell cycle control.

### References

1. Construction of lentiviral shRNA expression vector targeting phospholipase D2 (PLD2) gene??. Lian XF, Yu

CX, He XL, Lin JJ, Chen YZ, Zhu L.African Journal of Biotechnology Vol. 10 (66), pp. 15044-15050, 26 October, 20112.Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines.Somers-Edgar TJ, Taurin S, Larsen L, Chandramouli A, Nelson MA, Rosengren RJ.Invest New Drugs. 2009 Oct 9. [Epub ahead of print]

#### Images



# Citations

- The transcription factors Slug (SNAI2) and Snail (SNAI1) regulate phospholipase D (PLD) promoter in opposite ways towards cancer cell invasion.
- Downregulation of miRs 203, 887, 3619 and 182 prevent vimentin-triggered, phospholipase D (PLD)-mediated cancer cell invasion.
- Phospholipase D facilitates efficient entry of influenza virus allowing escape from innate mmune inhibition.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.